Halozyme Therapeutics Names Helen Torley CEO

(RTTNews) - Biopharmaceuticals company Halozyme Therapeutics Inc. (HALO) Tuesday named Helen Torley as its president and chief executive officer, effective January 6, 2014. She will also become a member of Halozyme's Board of Directors.

Torley was most recently executive vice president and chief commercial officer at Onyx Pharmaceuticals, a subsidiary of Amgen.

The company also said that Gregory Frost is departing Halozyme for Intrexon (XON), assuming the head of that company's Health Sector, and will continue to lead Halozyme's Scientific Advisory Board.

"Helen's demonstrated leadership of Onyx's oncology products will build on Halozyme's trajectory of value creation, pivoting from partnered to proprietary products," said Kenneth Kelley, chairman of the Board of Directors of Halozyme.

Prior to Onyx, Torley spent 14 years in management positions at Amgen, first in the Nephrology Business Unit, later in the Bone Health Business Unit. She held various senior positions at Bristol Myers Squibb.